

Novacyt S.A.
("Novacyt" or the "Company")

Update on Notice of 2020 Full Year Results

Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (Euronext Growth: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited financial results for the year ended 31 December 2020 on Tuesday 22 June 2021.

The Company has changed its reporting currency from Euro to Great British Pounds (GBP) for these results, and will report in GBP going forward, as the cost base of the business is now mainly located in the UK and GBP is the largest invoicing currency for sales. The results for the year ended 31 December 2019 will be restated to GBP to provide the same currency comparison.

- End -

Novacyt SA

Graham Mullis, Chief Executive Officer
James McCarthy, Chief Financial Officer
+44 (0)1276 600081

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470

Numis Securities Limited (Joint Broker)

Freddie Barnfield / James Black
+44 (0)20 7260 1000

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com; y.petit@allegrafinance.com

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com / alex.shaw@fticonsulting.com /
Novacyt.group@fticonsulting.com

FTI Consulting (France)

Arnaud de Cheffontaines
+33 (0)147 03 69 48
arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of *in vitro* and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The



Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information, please refer to the website: www.novacyt.com